Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Allergy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
COPD. 2023 Dec;20(1):197-209. doi: 10.1080/15412555.2023.2187210.
Chronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on bronchodilators and corticosteroids, cannot consider all COPD populations. Moreover, the present treatment modalities are directed at minimizing symptoms and reducing the risk of a future attack, but they exhibit few meaningful anti-inflammatory activities in preventing and reducing disease progression. Therefore, new anti-inflammatory molecules are needed to manage COPD better. Use of targeted biotherapy may obtain better results by increasing understanding of the underlying inflammatory process and identifying new biomarkers. In this review, we focus briefly on study of the underlying inflammatory process in the pathogenesis of COPD for better identification of novel target biomarkers, and we describe a novel class of anti-inflammatory biologics that are already under evaluation for their use in managing COPD.
慢性阻塞性肺疾病（COPD）是一种慢性、复杂且异质性的疾病，具有显著的死亡率、发病率和社会经济负担。鉴于其异质性，目前 COPD 的管理主要依赖于支气管扩张剂和皮质类固醇，无法考虑所有 COPD 人群。此外，目前的治疗方法旨在最大限度地减轻症状和降低未来发作的风险，但在预防和减少疾病进展方面几乎没有发挥有意义的抗炎作用。因此，需要新的抗炎分子来更好地管理 COPD。通过增加对潜在炎症过程的理解和识别新的生物标志物，使用靶向生物疗法可能会获得更好的效果。在这篇综述中，我们简要地关注了 COPD 发病机制中潜在炎症过程的研究，以更好地识别新的靶向生物标志物，并描述了一类新的抗炎生物制剂，它们已经在评估用于管理 COPD。
